Exagen Inc
Research Exagen Inc (XGN) on Bullrun: market cap USD 183.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 183.87M
- Financial periodQ2 2026
- RevenueUSD 19.94M
- Net income-USD 3.20M
- Free cash flowUSD 3.45M
- Gross margin61.3%
Valuation Snapshot
latest market cap is USD 183.87M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 66.58M | -USD 19.95M | -USD 14.27M | 58.3% | -0.93 | USD 32.22M | USD 22.91M | USD 17.45M |
| FY2024 | USD 55.64M | -USD 15.12M | -USD 13.79M | 59.5% | -0.83 | USD 22.04M | USD 20.25M | USD 9.54M |
| FY2023 | USD 52.55M | -USD 23.69M | -USD 15.29M | 56.1% | -1.34 | USD 36.49M | USD 19.50M | USD 22.69M |
| FY2022 | USD 45.56M | -USD 47.39M | -USD 36.46M | 46.9% | -2.77 | USD 62.39M | USD 28.97M | USD 42.46M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 183.87M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 139.30M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 72.33M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 33.92M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 39.17M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 188.00M | n/a | n/a | n/a |
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Exagen Inc's market cap?
Exagen Inc's market capitalization is USD 183.87M.
What does Exagen Inc do?
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).